FOXO4-DRI vs Klotho
A side-by-side research comparison of FOXO4-DRI and Klotho across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Klotho |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Klotho Protein |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Research compound (preclinical/early) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Exists in membrane-bound and soluble forms. Soluble Klotho acts as a circulating hormone that modulates FGF23 signaling, regulates phosphate/vitamin D balance, suppresses certain growth and oxidative-stress pathways, and supports synaptic and cognitive function. |
| Molecular weight | ~4,500 Da | ~130 kDa (full protein; fragments studied) |
| Half-life | 12-24 hours (D-amino acid stability) | Not well established for therapeutic forms |
| Bioavailability | Moderate (SubQ) | Injectable in research; large protein with limited oral absorption |
| Typical dose | 5-10 mg/kg (animal studies) | No established human dose |
| Frequency | 3x per week for 3 weeks | Unknown |
| Route | Subcutaneous | Injection (research) |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Klotho reported benefits
- Associated with longevity and slower aging
- Neuroprotection and improved cognition (preclinical)
- Supports kidney and cardiovascular health
- Regulates phosphate and mineral balance
Related comparisons
Research and educational reference only. Not medical advice.